p-cd19cd20-allo1
p-cd19cd20-allo1: sourced relationships with 1 company · 1 clinical trial tracked.
p-cd19cd20-allo1 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect p-cd19cd20-allo1 to PSTX; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could p-cd19cd20-allo1 → PSTX affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Poseida Therapeutics, Inc. (PSTX) Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 |
Clinical Trial Registry Records (1)
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies
Primary endpoint: Assess the safety and MTD or RDE of P-CD19CD20-ALLO1 based on dose limiting toxicities (DLT)
Interventionalopen120 targetStarted 2024-04Completion 2041-0317 sites · United StatesPoseida Therapeutics, Inc.
Frequently asked questions
Which companies have sourced relationships with p-cd19cd20-allo1?
p-cd19cd20-allo1 has dated SEC/FDA relationship records for Poseida Therapeutics, Inc..
How many clinical trials involve p-cd19cd20-allo1?
BioSniper tracks 1 clinical trial involving p-cd19cd20-allo1.